Mozavaptan
A vasopressin V2 receptor antagonist (vaptanclass) used in Japan to treat hyponatremia (low blood sodium) associated with liver cirrhosis. By blocking vasopressin's action on the kidney, it promotes free water excretion and raises blood sodium levels.
Peso molecular
427,5000 g/mol
LogP
4,50
TPSA
52,70 Ų
Regla de cinco de Lipinski
Cumple
Mecanismo de acción
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Estructura 2D
Cite this structure
Embed this structure
SMILES
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(N(C)C)c3ccccc32)cc1
InChI
InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)
Molecular Formula
C27H29N3O2
HBD / HBA
1 / 3
Enlaces Rotables
4
Átomos Pesados
32
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A vasopressin V2 receptor antagonist (vaptanclass) used in Japan to treat hyponatremia (low blood sodium) associated with liver cirrhosis. By blocking vasopressin's action on the kidney, it promotes free water excretion and raises blood sodium levels.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Mozavaptan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL420762. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 119369. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="mozavaptan"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/mozavaptan/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/mozavaptan/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/mozavaptan/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="mozavaptan"></drugfyi-drug>